Paul Herrling - Evotec AG Insider

EVOTF -- USA Stock  

USD 17.48  0.00  0.00%

Member of the Supervisory Board
Prof
Age: 64  Executive Since 2014  Ph.D    
49 40 5 60 81 0  http://www.evotec.com
Paul Linus Herrling, Ph.D., was Member of the Supervisory Board at Evotec AG from June 17, 2014 till 2017. He was Member of the Remuneration and Nomination Committee at the Company. He is former head of global research of Novartis Pharma AG. He is Chairman of the Board at Novartis Institute for Tropical Disease Ltd. Member of Board of Novarits Institute for Functional Genomics La Jolla and Novarits International Pharmaceuticals, Hamilton. He is also Vice President of Eidgenossische Technische Hochschule.

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance Indicators

Current Sentiment - EVOTF

Evotec AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Evotec AG. What is your opinion about investing in Evotec AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and China Steel. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.